Anti-tmprss2 antibodies and antigen-binding fragments
AssigneeRegeneron Pharmaceuticals, Inc.
InventorLisa PURCELL
Life of this patent
Estimating the term…
Abstract
The present invention includes an antibody or antigen-binding fragment thereof that binds specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., influenza virus infections).
Claims21
1-23. (canceled)
A method for treating or preventing cancer or infection with an influenza virus, coronavirus, SARS-Co virus, MERS-Co virus, parainfluenza virus, human metapneumovirus or hepatitis C virus (HCV), in a subject in need thereof, comprising administering a therapeutically effective amount of an antigen-binding protein that specifically binds to human TMPRSS2 comprising:
- (a) an immunoglobulin heavy chain variable region comprising the CDR-H1, CDR-H2, and CDR-H3 of an immunoglobulin heavy chain that comprises the amino acid sequence set forth in SEQ ID NO:
- 2, 17 or 19;
- and/or
- (b) an immunoglobulin light chain variable region comprising the CDR-L1, CDR-L2, and CDR-L3 of an immunoglobulin light chain that comprises the amino acid sequence set forth in SEQ ID NO:
- 4 or 18.
A method for administering an antigen-binding protein that specifically binds to human TMPRSS2 into the body of a subject, wherein the antigen-binding protein comprises:
- (a) an immunoglobulin heavy chain variable region comprising the CDR-H1, CDR-H2, and CDR-H3 of an immunoglobulin heavy chain that comprises the amino acid sequence set forth in SEQ ID NO:
- 2, 17 or 19;
- and/or
- (b) an immunoglobulin light chain variable region comprising the CDR-L1, CDR-L2, and CDR-L3 of an immunoglobulin light chain that comprises the amino acid sequence set forth in SEQ ID NO:
- 4 or 18;
- the method comprising injecting the antigen-binding protein into the body of the subject.
Dependencies are inferred from the claim text.